IP Library Granted Patent US 9,616,120
Granted Patent B2
US 9,616,120 · App. 13/048,135 · Granted Apr 11, 2017

Monoclonal antibodies directed to CD20

Inventor: Genevieve Hansen (Del Mar, CA)
Assignee: VET THERAPEUTICS, INC.
A61K39/395C07H21/00C07K16/28C07K16/2887C07K2316/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,616,120
App. No.
13/048,135
Granted
Apr 11, 2017
Kind
B2
Abstract

The invention provides antibody to canine or feline or equine antigens. Specifically, antibodies directed to canine CD20 which have been caninized or felinized are provided. Also provided are methods for preparing high affinity antibodies to canine and feline CD20 as well as methods for treating B cell disorders in companion animals.

Claims (11)

1. An antibody or antibody fragment recognizing a canine or feline CD20, wherein said antibody or antibody fragment comprises a light chain comprising a sequence selected from SEQ ID NOs: 24, 25, and 39, and a heavy chain comprising a sequence selected from SEQ ID NOs: 23, and 38.

2. The antibody or antibody fragment according to claim 1 which is a heterochimeric antibody.

3. The antibody or antibody fragment according to claim 1 which binds to canine CD20 and wherein the antibody or antibody fragment comprises a constant region and where the constant region is of canine origin.

4. The antibody or antibody fragment according to claim 1 which binds to feline CD20.

5. The antibody or antibody fragment claim 1 comprising a constant domain, wherein the constant domain comprises a sequence selected for providing enhanced ADCC and/or CDC.

6. The antibody or antibody fragment of claim 1 recognizing a canine or feline CD20, and wherein the heavy chain comprises SEQ ID NO: 23.

7. The antibody or antibody fragment of claim 1 recognizing a canine or feline CD20, and wherein the light chain comprises SEQ ID NO: 24.

8. The antibody or antibody fragment of claim 1 recognizing a canine or feline CD20, and wherein the light chain comprises SEQ ID NO: 25.

9. The antibody or antibody fragment of claim 1 recognizing a canine or feline CD20, and wherein the heavy chain comprises SEQ ID NO: 38.

10. The antibody or antibody fragment of claim 1 recognizing a canine or feline CD20, and wherein the light chain comprises SEQ ID NO: 39.

11. The antibody or antibody fragment of claim 1 recognizing a canine or feline CD20, and wherein the heavy chain comprises SEQ ID NO: 38 and wherein the light chain comprises SEQ ID NO: 39.

Assignments (2)
MERGER Recorded Sep 6, 2017
From: VET THERAPEUTICS, INC.
To: ARATANA THERAPEUTICS, INC.
Reel/Frame 043773/0348 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2011
From: HANSEN, GENEVIEVE
To: VET THERAPEUTICS, INC.
Reel/Frame 026106/0206 →
Continuity (3)
Continuation PCTUS2011000415 · Mar 4, 2011
Provisional Application 61310440 · Mar 4, 2010
Related Publication 20110217298A1 · Sep 8, 2011